Candesartan treatment for peripheral occlusive arterial disease after stent angioplasty: A randomised, placebo-controlled trial

Clinical Drug Investigation

Volumn 25, Issue 2, 2005, Pages 89-97

  Schindler, C ^a   Schweizer, J ^b   Muller A ^b   Koch, R ^c   Hellner, G ^b   Fuchs, W ^d   Kirch, W ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d Takeda Pharma ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; CANDESARTAN; PIRETANIDE; PLACEBO;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; FEMORAL ARTERY; HUMAN; HYPOTHESIS; INTIMA; ISCHEMIC HEART DISEASE; MALE; PAIN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; SIDE EFFECT; TREATMENT OUTCOME; WALKING;

EID: 14644419561     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525020-00001     Document Type: Article

References (34)

1. Duda SH, Poerner TC, Wiesinger B, et al. Drug-eluting stents: potential applications for peripheral arterial occlusive disease. J Vase Interv Radiol 2003; 14: 291-301
2. Ludwig M, Stapff M, Ribeiro A, et al. Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study. Clin Ther 2002; 24: 1175-93
3. Shah PK. The calcium channel blocker lacidipine slows the progression of carotid atherosclerosis. Rev Cardiovasc Med 2003; 4: 191-2
4. McCormack P, Wagstaff A. Lacidipine: a review of its use in the management of hypertension. Drugs 2003; 63: 2327-56
5. Kohno M, Ohmori K, Nozaki S, et al. Effects of valsartan on angiotensin II-induced migration of human coronary artery smooth muscle cells. Hypertens Res 2000; 23: 677-81
6. Bell L, Madri JA. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol 1990; 137: 7-12
7. Daemen MJ, Lombardi DM, Bosman FT, et al. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991; 68: 450-6
8. Meurice T, Bauters C, Hermant X, et al. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Lancet 2001; 357: 1321-4
9. Desmet W, Vrolix M, De Scheerder I, et al. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Circulation 1994; 89: 385-92
10. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 1995; 25: 362-9
11. Janiak P, Libert O, Vilaine JP. Role of the renin-angiotensin system in neointima formation after injury in rabbits. Hypertension 1994; 24: 671-8
12. Nozawa Y, Matsuura N, Miyake H, et al. Effects of TH-142177 on angiotensin II-induced proliferation, migration and intracellular signaling in vascular smooth muscle cells and on neointimal thickening after balloon injury. Life Sci 1999; 64: 2061-70
13. Wilson DP, Saward L, Zahradka P, et al. Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model. Cardiovasc Res 1999; 42: 761-72
14. Kawamura M, Terashita Z, Okuda H, et al. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats. J Pharmacol Exp Ther 1993; 266: 1664-9
15. Peters S, Gotting B, Trummel M, et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001; 13: 93-7
16. Wakeyama T, Ogawa H, Iida H, et al. Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial. Circ J 2003; 67: 519-24
17. Wagner HJ. Current status of endovascular therapy in the femoropopliteal vascular segment in chronic peripheral arterial occlusive disease [review in German]. Vasa 2002; 31: 153-61
18. Schweizer J, Kirch W, Koch R, et al. Effect of high dose verapamil on restenosis after peripheral angioplasty. J Am Coll Cardiol 1998; 31: 1299-305
19. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66
20. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71
21. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6
22. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-81
23. Seeger H, Wallwiener D, Mueck AO. Class-specific inhibition of angiotensin II-induced proliferation of human smooth muscle cells by ATI-antagonists [abstract]. Atheroscler Suppl 2001; 2: 148
24. Khaper N, Singal PK. Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. J Am Coll Cardiol 2001; 37: 1461-6
25. Smilde TJ, Wollersheim H, Van Langen H, et al. Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness. Clin Sci (Lond) 1997; 93: 317-24
26. Simon A, Gariepy J, Chironi G, et al. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 2002; 20: 159-69
27. Gariepy J, Massonneau M, Levenson J, et al. Evidence for in vivo carotid and femoral wall thickening in human hypertension. Groupe de Prevention Cardio-vasculaire en Medecine du Travail. Hypertension 1993; 22: 111-8
28. Kanters SD, Algra A, van Leeuwen MS, et al. Reproducibility of in vivo carotid intima-media thickness measurements: a review. Stroke 1997; 28: 665-71
29. O'Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002; 90: 18L-21L
30. Ludwig MM, Jörger U, Winter U, et al. Diagnostik früher Veränderungen der arteriellen Gefaßwandstruktur mit hochauflösenden Sonographieverfahren. Herz/Kreisl 1995; 27: 172-8
31. Neutel JM, Weir MR, Moser M, et al. The effects of candesartan cilexetil in isolated systolic hypertension: a clinical experience trial. J Clin Hypertens (Greenwich) 2000; 2: 181-6
32. Mitchell GF, Moye LA, Braunwald E, et al. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. Circulation 1997; 96: 4254-60
33. Schrader J, Luders S, Kulschewski A, et al. The ACCESS study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699-703
34. Belz GG. Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology. Br J Clin Pharmacol 2003; 56: 3-10